ERBB2 and triple-negative breast carcinoma: This pre-clinical study showed that neratinib and dasatinib have remarkable nanomolar synergistic anti-proliferative activity in models of HER2+ and triple negative breast cancers, and the combination treatment was capable of overcoming HER2-targeted TKI resistance.